Important Safety Information

Before starting KRYSTEXXA® (pegloticase), you should know that:

KRYSTEXXA is for adults who have tried or can not take oral gout medicines and still have high uric acid levels and gout signs and symptoms, also known as Refractory Chronic Gout.

KRYSTEXXA is not recommended if you have high levels of uric acid without signs and symptoms of gout.

You should not use KRYSTEXXA if you have a genetic condition known as G6PD deficiency, which stands for glucose-6-phosphate dehydrogenase deficiency. This is also known as favism. G6PD deficiency occurs more often in people of African or Mediterranean family background. However, it can occur in anyone. Before giving you KRYSTEXXA, your doctor may give you a blood test to determine if you have G6PD deficiency.

Before you receive KRYSTEXXA, tell your doctor if you:

  • Know you have G6PD deficiency
  • Have, or ever had, heart problems or high blood pressure
  • Are pregnant or planning to become pregnant. It is not known if KRYSTEXXA will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed. It is not known if KRYSTEXXA passes into your breast milk. You and your doctor should decide if you will receive KRYSTEXXA or breastfeed

What is the most important information I should know about KRYSTEXXA?

Serious allergic reactions may happen in some people who receive KRYSTEXXA. These allergic reactions can be life threatening and usually happen within 2 hours of the infusion.

KRYSTEXXA should be given to you by a doctor or nurse in a healthcare setting where serious allergic reactions can be treated. Your doctor or nurse should watch you for any signs of a serious allergic reaction during and after your treatment with KRYSTEXXA.

Tell your doctor or nurse right away if you have any of these symptoms during or after your treatment with KRYSTEXXA:

  • Wheezing, shortness of breath, cough, chest tightness, chest pain, or trouble breathing
  • Dizziness, fainting, fast or weak heartbeat or feeling nervous
  • Reddening of the face, itching, hives, or feeling warm
  • Swelling of the throat or tongue, throat tightness, hoarse voice or trouble swallowing

There are possible side effects with KRYSTEXXA:

The most common serious side effects in patients taking KRYSTEXXA were severe allergic reactions and infusion reactions. The most common side effects were gout flare-ups or attacks, infusion reactions, nausea, bruising, sore throat, constipation, chest pain, severe allergic reactions, and vomiting.

An increase in gout flares is frequently observed in patients when they start taking medicines to lower their uric acid levels. Patients do not need to stop taking KRYSTEXXA simply because of gout flares.

This is not a complete list of all possible side effects. Ask your doctor or treatment team if you have any questions or want more information.

If you have any questions about KRYSTEXXA or your therapy, talk with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call the FDA at 1-800-FDA-1088.

Please see the Medication Guide and Prescribing Information, including Boxed Warning, for more information.

© 2013 Savient Pharmaceuticals, Inc. All rights reserved.

Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.

This site is published by Savient Pharmaceuticals, Inc. which is solely responsible for its contents. This information is intended for the use of our customers, patients, and healthcare professionals in the United States only. Savient recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States. Capitalized product names are trademarks of Savient.

Some documents on this site are stored in Adobe PDF format and require the free Adobe® Reader® to view.